GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Net Income From Continuing Operations

Accelerated Pharma (Accelerated Pharma) Net Income From Continuing Operations : $-2.86 Mil (TTM As of Mar. 2017)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Accelerated Pharma's net income from continuing operations for the three months ended in Mar. 2017 was $-0.64 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2017 was $-2.86 Mil.


Accelerated Pharma Net Income From Continuing Operations Historical Data

The historical data trend for Accelerated Pharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Net Income From Continuing Operations Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Net Income From Continuing Operations
- -4.18 -3.93

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Net Income From Continuing Operations Get a 7-Day Free Trial -1.71 -0.77 -0.85 -0.60 -0.64

Accelerated Pharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accelerated Pharma (Accelerated Pharma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines